Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications

Optimising infliximab induction dosing for patients with ulcerative colitis

(2019) Erwin Dreesen et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers

(2019) Mayu Osawa et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pharmacokinetics and Pharmacodynamics of LY2599666, a PEG-Linked Antigen Binding Fragment that Targets Soluble Monomer Amyloid-β

(2019) Li Li et al.   JOURNAL OF ALZHEIMERS DISEASE

Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer

(2019) Edwin A. Basak et al.   EUROPEAN JOURNAL OF CANCER

Pharmacokinetic parameters of infliximab influence the rate of relapse after de-escalation in adults with inflammatory bowel diseases

(2019) Antoine Petitcollin et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis

(2019) Petra Jauslin et al.   CLINICAL PHARMACOKINETICS

Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis

(2019) Christine Xu et al.   CLINICAL PHARMACOKINETICS

Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials

(2019) Ahmed A. Suleiman et al.   CLINICAL PHARMACOKINETICS

Nivolumab Clearance Is Stationary in Resected Melanoma Patients on Adjuvant Therapy: Implications of Disease Status on Time‐Varying Clearance

(2019) Lora Hamuro et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies

(2019) Ken Ogasawara et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis

(2019) Amit Khatri et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients

(2019) Daan P. Hurkmans et al.   Journal for ImmunoTherapy of Cancer

CD4+ count‐dependent concentration‐effect relationship of rituximab in rheumatoid arthritis

(2019) Amina Bensalem et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Population pharmacokinetics of siltuximab: impact of disease state

(2019) Mina Nikanjam et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review

(2019) Antoine Petitcollin et al.   CLINICAL PHARMACOKINETICS

A Population Pharmacokinetic and Exposure–Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis

(2019) Erwin Dreesen et al.   INFLAMMATORY BOWEL DISEASES

Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited

(2019) Amina Bensalem et al.   CLINICAL PHARMACOKINETICS

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

(2019) Colby S. Shemesh et al.   Journal for ImmunoTherapy of Cancer

Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease

(2018) Niels Vande Casteele et al.   CLINICAL PHARMACOKINETICS

Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis–Menten Approximation of a Target-Mediated Drug Disposition Model—Support for a Biologics License Application Submission: Part I

(2018) Jean-Marie Martinez et al.   CLINICAL PHARMACOKINETICS

Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans

(2018) David Ternant et al.   CLINICAL PHARMACOKINETICS

Population Pharmacokinetics of Gemtuzumab Ozogamicin in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia

(2018) Joanna C. Masters et al.   CLINICAL PHARMACOKINETICS

Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status

(2018) Paul G. Baverel et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies

(2018) Paul Malik et al.   Expert Opinion on Drug Metabolism & Toxicology

Modeling Immunization To Infliximab in Children With Crohn’s Disease Using Population Pharmacokinetics: A Pilot Study

(2018) Antoine Petitcollin et al.   INFLAMMATORY BOWEL DISEASES

Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System

(2018) Alexander Eser et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis

(2018) Zhenling Yao et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients With Moderately to Severely Active Rheumatoid Arthritis

(2018) Yan Xu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia

(2018) Mita Kuchimanchi et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohnʼs Disease

(2018) Sophie E. Berends et al.   THERAPEUTIC DRUG MONITORING

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

(2018) G V Long et al.   ANNALS OF ONCOLOGY

Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials

(2018) Ahmed A. Suleiman et al.   CLINICAL PHARMACOKINETICS

Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia

(2018) Jennifer Hibma et al.   CLINICAL PHARMACOKINETICS

Population pharmacokinetics and pharmacodynamics of bezlotoxumab in adults with primary and recurrent Clostridium difficile infection

(2018) Ka Lai Yee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetics and Exposure - Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

(2018) Xiaoli Wang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease

(2017) Johannan F. Brandse et al.   INFLAMMATORY BOWEL DISEASES

Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling and Simulation

(2017) Tomohisa Saito et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Alternative Treatment Regimens With the PCSK9 Inhibitors Alirocumab and Evolocumab: A Pharmacokinetic and Pharmacodynamic Modeling Approach

(2017) Nina Scherer et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis

(2017) Kumar Kandadi Muralidharan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

(2017) Hongshan Li et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects

(2017) Thuy Vu et al.   PHARMACEUTICAL RESEARCH

Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma

(2017) Rui Zhu et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases

(2017) Gilles Paintaud et al.   THERAPEUTIC DRUG MONITORING

Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic–Pharmacodynamic Modeling

(2017) Christophe Passot et al.   THERAPEUTIC DRUG MONITORING

Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation

(2016) Sonata Jodele et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain

(2016) E. Niclas Jonsson et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer

(2016) Guillemette Bernadou et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors

(2016) Satoshi Yoshiba et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Population pharmacokinetics of bevacizumab in cancer patients with external validation

(2016) Kelong Han et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I–III Clinical Trials

(2016) Lei Diao et al.   CLINICAL PHARMACOKINETICS

Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients

(2016) Morgane Caulet et al.   CLINICAL PHARMACOKINETICS

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group

(2016) Mira Tout et al.   CLINICAL PHARMACOKINETICS

Ethnic sensitivity assessment of pharmacokinetics and pharmacodynamics of omalizumab with dosing table expansion

(2016) Wataru Honma et al.   Drug Metabolism and Pharmacokinetics

Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis

(2016) Haiying Sun et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma

(2016) Leonid Gibiansky et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis

(2016) N.M. Mostafa et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The underlying inflammatory chronic disease influences infliximab pharmacokinetics

(2016) Christophe Passot et al.   mAbs

Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors

(2016) Shawn M Davidson et al.   NATURE MEDICINE

Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients

(2016) Tong Shen et al.   PHARMACEUTICAL RESEARCH

Pharmacokinetics interactions of monoclonal antibodies

(2016) Nicola Ferri et al.   PHARMACOLOGICAL RESEARCH

Quantitative Histomorphometry of the Healthy Peritoneum

(2016) Betti Schaefer et al.   Scientific Reports

Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

(2015) M. Rosario et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice

(2015) D. J. Buurman et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients

(2015) Fei Hua et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation

(2015) Kelong Han et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing

(2015) Paul G. Baverel et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR

(2015) Shringi Sharma et al.   CLINICAL PHARMACOKINETICS

Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis

(2015) David Ternant et al.   CLINICAL PHARMACOKINETICS

A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS)

(2015) David Ternant et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics of adalimumab in Crohn’s disease

(2015) David Ternant et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics and Exposure–Efficacy Relationship of Adalimumab in Pediatric Patients with Moderate to Severe Crohnʼs Disease

(2015) Shringi Sharma et al.   INFLAMMATORY BOWEL DISEASES

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease

(2015) Janet R. Wade et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Population pharmacokinetic and pharmacodynamic analyses from a 4-month intradose escalation and its subsequent 12-month dose titration studies for a human monoclonal anti-FGF23 antibody (KRN23) in adults with X-linked hypophosphatemia

(2015) Xiaoping Zhang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies

(2015) Diane R. Mould et al.   JOURNAL OF CLINICAL PHARMACOLOGY

IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding

(2015) David Ternant et al.   JOURNAL OF IMMUNOLOGY

Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule

(2015) Philippe Gatault et al.   mAbs

Issue Information

(2015)   JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetic Modeling of LY2189102 after Multiple Intravenous and Subcutaneous Administrations

(2014) Sébastien Bihorel et al.   AAPS Journal

Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma

(2014) Yan Feng et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors

(2014) Amit Garg et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer

(2014) Valérie F. Cosson et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

PCSK9 and lipid lowering drugs

(2014) Yuan-Lin Guo et al.   CLINICA CHIMICA ACTA

Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease

(2014) David Ternant et al.   CLINICAL PHARMACOKINETICS

Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease

(2014) Iris Dotan et al.   INFLAMMATORY BOWEL DISEASES

Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis

(2014) Herbert Struemper et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma

(2014) Erjian Wang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies

(2014) Christopher J. Endres et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease

(2014) Chuanpu Hu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models

(2014) Ludivine Fronton et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Pharmacokinetics of Ranibizumab after Intravitreal Administration in Patients with Retinal Vein Occlusion or Diabetic Macular Edema

(2014) Yi Zhang et al.   OPHTHALMOLOGY

Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation

(2013) Pauline A van Schouwenburg et al.   ANNALS OF THE RHEUMATIC DISEASES

Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis

(2013) David Ternant et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma

(2013) Y. Feng et al.   CLINICAL CANCER RESEARCH

Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus

(2013) Rajesh Narwal et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies

(2013) Miroslav Dostalek et al.   CLINICAL PHARMACOKINETICS

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab

(2013) Bella Ungar et al.   GUT

Population Pharmacokinetics of Belimumab Following Intravenous Administration in Patients With Systemic Lupus Erythematosus

(2013) Herbert Struemper et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis

(2013) Abhijit Chakraborty et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetics of Rilotumumab, a Fully Human Monoclonal Antibody Against Hepatocyte Growth Factor, in Cancer Patients

(2013) Min Zhu et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Distribution of rat neonatal Fc receptor in the principal organs of neonatal and pubertal rats

(2013) Zehua Tian et al.   JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION

Influence ofFCGRTgene polymorphisms on pharmacokinetics of therapeutic antibodies

(2013) Christophe Passot et al.   mAbs

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

(2012) Sandra Garcês et al.   ANNALS OF THE RHEUMATIC DISEASES

Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody, in Adults and Children

(2012) Gabriel J. Robbie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

(2012) C. Muller et al.   BLOOD

Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours

(2012) Leonid Gibiansky et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody

(2012) Abhijit Chakraborty et al.   CLINICAL PHARMACOKINETICS

Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?

(2012) Rong Deng et al.   Expert Opinion on Drug Metabolism & Toxicology

Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients

(2011) N. Azzopardi et al.   CLINICAL CANCER RESEARCH

Population Pharmacokinetic Meta-Analysis of Denosumab in Healthy Subjects and Postmenopausal Women with Osteopenia or Osteoporosis

(2011) Liviawati Sutjandra et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials

(2011) Adedigbo A. Fasanmade et al.   CLINICAL THERAPEUTICS

Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2-Targeted Antibody-Drug Conjugate, in Patients With HER2-Positive Metastatic Breast Cancer

(2011) Manish Gupta et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature

(2011) Digant Gupta et al.   Nutrition Journal

Population PK and IgE Pharmacodynamic Analysis of a Fully Human Monoclonal Antibody Against IL4 Receptor

(2011) Tarundeep Kakkar et al.   PHARMACEUTICAL RESEARCH

Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies

(2010) Diane R. Mould et al.   BIODRUGS

Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer

(2010) B Royer et al.   BRITISH JOURNAL OF CANCER

Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint

(2010) Stephen B. Duffull et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Nathanael L. Dirks et al.   CLINICAL PHARMACOKINETICS

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Ron J. Keizer et al.   CLINICAL PHARMACOKINETICS

Translational Pharmacokinetics and Pharmacodynamics of an FcRn-Variant Anti-CD4 Monoclonal Antibody From Preclinical Model to Phase I Study

(2010) Y Zheng et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis

(2010) Nicolas Frey et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Population Approach for Exposure-Response Modeling of Golimumab in Patients With Rheumatoid Arthritis

(2010) Chuanpu Hu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Functional Capillary Density Decreases after the First Week of Life in Term Neonates

(2010) A.P.C. Top et al.   Neonatology

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review

(2010) Charlotte Krieckaert et al.   ARTHRITIS RESEARCH & THERAPY

Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease

(2009) Mohammad Tabrizi et al.   AAPS Journal

Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis

(2009) R M Thurlings et al.   ANNALS OF THE RHEUMATIC DISEASES

Refinement of the Population Pharmacokinetic Model for the Monoclonal Antibody Matuzumab

(2009) Katharina Kuester et al.   CLINICAL PHARMACOKINETICS

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

(2009) Adedigbo A. Fasanmade et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics

(2009) Leonid Gibiansky et al.   Expert Opinion on Drug Metabolism & Toxicology

Population Pharmacokinetic Analysis of Panitumumab in Patients With Advanced Solid Tumors

(2009) Peiming Ma et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetics of Golimumab, an Anti-Tumor Necrosis Factor-α Human Monoclonal Antibody, in Patients With Psoriatic Arthritis

(2009) Zhenhua Xu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

(2009) Yaowei Zhu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients

(2009) David Ternant et al.   THERAPEUTIC DRUG MONITORING

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

(2008) Jian-Feng Lu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

(2008) W Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Population Pharmacokinetics of Cetuximab in Patients With Squamous Cell Carcinoma of the Head and Neck

(2008) Nathanae L. Dirks et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis

(2008) Zhenhua Xu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Approximations of the target-mediated drug disposition model and identifiability of model parameters

(2008) Leonid Gibiansky et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

(2008) Janice Mayne et al.   Lipids in Health and Disease

Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients

(2007) Mark D. Pescovitz et al.   PEDIATRIC TRANSPLANTATION